The Society for Neuro-Oncology (SNO) and WFNOS Annual Meeting is one of the most important gatherings of clinicians, researchers, and innovators working to improve outcomes for patients with central nervous system (CNS) cancers. This year, CNSide Diagnostics is proud to participate and showcase the latest advancements in cerebrospinal fluid (CSF)–based tumor detection and characterization.

If you’re attending the meeting, be sure to visit CNSide Diagnostics at Booth #315 and the Plus Therapeutics (PSTV) team at Booth #317 to learn more about how both organizations are working together to transform the diagnosis and management of complex CNS malignancies.

Discover What’s New at the CNSide Diagnostics Booth (#315)

At SNO/WFNOS 2025, our team will highlight new developments across the CNSide® CSF Assay Platform, a comprehensive suite of tools designed to capture, enumerate, and characterize tumor cells and tumor-derived genetic material in CSF.

Attendees can explore:

• Enhanced CSF tumor cell enumeration (TCE) workflows that provide clinicians deeper insight into CNS disease burden
• Expanded molecular characterization capabilities, including ICC, FISH, and NGS-based profiling
• Improved sample preservation technologies designed to support more reliable downstream analyses
• Clinical use cases and research collaborations demonstrating how CNSide helps clinicians make faster, more informed decisions

Our goal is to equip physicians and researchers with high-quality, actionable diagnostic data that supports earlier detection, better monitoring, and more personalized therapeutic strategies for leptomeningeal metastases and other CNS cancers.

Visit Plus Therapeutics (PSTV) at Booth (#317)

Just steps away, Plus Therapeutics, our parent company, will be sharing updates on its targeted radiotherapeutic candidate REYOBIQ™, currently being evaluated in the ReSPECT-LM and ReSPECT-GBM clinical trials. The integration of precision diagnostics from CNSide and precision therapeutics from Plus Therapeutics represents a powerful and complementary approach to advancing patient care in neuro-oncology.

Why SNO/WFNOS Matters for the Future of CNS Cancer Care

With LM and other CNS malignancies continuing to present major diagnostic and therapeutic challenges, meetings like SNO/WFNOS bring together leaders committed to accelerating innovation. CNSide Diagnostics is honored to contribute to this scientific community and engage with partners who share our vision of improving outcomes for patients facing these difficult diseases.